Multiple Myeloma

MPR Weekly Dose Podcast Episode 105

This week: Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; Parsaclisib’s NDA withdrawn; New data produces a reconsideration for Pepaxto withdrawal; And there’s a new treatment approval for unresectable or metastatic uveal melanoma.

MPR Weekly Dose Podcast Episode 98

FDA Advisory Committee votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.